Seminoma patients treated at a minor oncological department during 1986-2010: treatment and outcome

Anticancer Res. 2014 Aug;34(8):4253-60.

Abstract

Aim: To present results for patients with seminoma treated at our University Clinic.

Patients and methods: All men treated for seminoma in 1986-2010 at the Department of Oncology, University Hospital of North Norway were included (n=232). Treatment was standardized from 2000 as the Swedish and Norwegian Testicular Cancer Project (SWENOTECA) published their first standardised seminoma treatment program (SWENOTECA V).

Results: The percentage of patients administered adjuvant radiotherapy (RT) for clinical stage (CS) I decreased gradually from the late 1990s and was abandoned in 2005. Surveillance was the most common management strategy for CS I after 2000. Overall, disease in 1.9% and 11% of patients relapsed after adjuvant RT and surveillance, respectively. There were no relapses after treatment for metastatic disease. Cancer-specific survival was 100%, and overall survival 95% for the total group.

Conclusion: The treatment outcome at our University Clinic is excellent with 100% cancer-specific survival, and is essentially a result of the bi-national SWENOTECA network.

Keywords: Seminoma; carboplatin; chemotherapy; radiotherapy; surveillance; survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Radiotherapy, Adjuvant
  • Seminoma / mortality
  • Seminoma / pathology
  • Seminoma / radiotherapy*
  • Testicular Neoplasms / mortality
  • Testicular Neoplasms / pathology
  • Testicular Neoplasms / radiotherapy*
  • Time Factors
  • Treatment Outcome